Pfizer announced that the World Health Organization has granted an expansion to the prequalification of Pfizer’s pneumococcal conjugate vaccine, Prevenar 13, to include adults 50 years of age and older against pneumonia and invasive disease caused by the 13 pneumococcal serotypes contained in the vaccine.
The Financial